Metraipolis › archive › dc_7e8771418316
CRISPR Genome Editing and the Future of Leukaemia Immunotherapy — Europe PMC PMID:42110387
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42110387
- DOI
- 10.1002/hsr2.72497
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T17:52:29.832Z
- SHA-256 of the archived text
ab97b27b758049d70a71a6ab21892104117720ed635b6fed49b5aaf67122c161- Stable URL of this page
https://metraipolis.com/documento/dc_7e8771418316
How to cite
CRISPR Genome Editing and the Future of Leukaemia Immunotherapy — Europe PMC PMID:42110387 — Europe PMC (en), https://europepmc.org/article/MED/42110387 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7e8771418316 (Metraipolis archive dc_7e8771418316, sha256 ab97b27b758049d70a71a6ab21892104117720ed635b6fed49b5aaf67122c161)
BibTeX
@misc{dc7e8771418316,
title = {CRISPR Genome Editing and the Future of Leukaemia Immunotherapy — Europe PMC PMID:42110387},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42110387},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7e8771418316; sha256 ab97b27b758049d70a71a6ab21892104117720ed635b6fed49b5aaf67122c161},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42110387. Agents can read the archived copy with the MCP tool read_document.